RedHill Biopharma Ltd.RDHL

Health Care · Pharmaceuticals, Biotechnology & Life Sciences · NASDAQ · Israel · redhillbio.com

RedHill Biopharma Ltd. is a specialty biopharmaceutical company primarily focused on U.S. development and commercialization of drugs for gastrointestinal diseases, infectious diseases and oncology. Its late-stage clinical pipeline includes opaganib (ABC294640), RHB-102 (Bekinda), RHB-204 and RHB-107 (upamostat). In August 2026 it divested Talicia to Apotex for $18 million upfront plus milestones.

Key ratios

FCF / Sales

-2515.8%TTM

2025 -2515.8%

Net margin

-150.0%TTM

2025 -150.0%

ROA

-22.8%2025

2024 -19.7%2023 -6.6%

Revenue growth

157.6%TTM

Recent news

RedHill Divests Talicia® to Apotex for $18 Million Cash Upfront Plus Milestones to Fuel Strategic Growth Opportunities 2026-08-31 · CNW

Track RDHL in your journal

Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.

Create a free account

Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer